Testing neratinib with or without palbociclib for HER2+ solid tumors
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that is HER2 positive (except breast cancer) and it has come back or not gone away after treatment.
- You have not taken a HER2-targeted pill like neratinib or tucatinib before.
- You have not taken a CDK4/6 inhibitor (a type of targeted therapy) before.
- You can have a new biopsy of your tumor, or you have stored tumor tissue from the past year.
- Your cancer is measurable on scans (a second tumor spot outside the biopsy site is needed).
- You have good kidney and liver function, and no serious lung or gut problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
This trial tests whether taking neratinib for one extra year can reduce the risk of breast cancer returning in women who had a complete response (no cancer found) after initial treatment but still have high-risk features. It is for women with HER2-positive early breast cancer.
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
This trial tests whether adding a second drug (neratinib) to standard hormone therapy can help women with a specific type of advanced breast cancer that has stopped responding to initial treatment. The goal is to see if the combination slows cancer growth better than hormone therapy alone.
Hear when a new Malignant Female Reproductive System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.